Payment overview · 2025
General Payments
$122.97
6 reported records · 2 companies
Healthcare provider profile · identity verified
John S Kelly, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · MICHIGAN CITY, IN · NPI 1033104849
Verified facts
What the public records show
CMS Open Payments records show John S Kelly, MD received $122.97 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 82.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.57 | 82.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.40 | 17.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.97 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.61 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 122 |
| Gabapentin | Gabapentin | 277 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 244 | 84 |
| Lisinopril | Lisinopril | 235 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 63 |
| Furosemide | Furosemide | 171 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 170 | 33 |
| Potassium Chloride | Potassium Chloride | 153 | 48 |
| Metformin Hcl | Metformin Hcl | 145 | 41 |
| Nitroglycerin | Nitroglycerin | 145 | 64 |
| Trazodone Hcl | Trazodone Hcl | 135 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 41 |
| Fluconazole | Fluconazole | 124 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 29 |
| Omeprazole | Omeprazole | 111 | 28 |
| Famotidine | Famotidine | 110 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 29 |
| Ozempic | Semaglutide | 97 | 19 |
| Carvedilol | Carvedilol | 95 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 21 |
| Spironolactone | Spironolactone | 83 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Prednisone | Prednisone | 80 | 27 |
| Amoxicillin | Amoxicillin | 79 | 49 |
| Azithromycin | Azithromycin | 79 | 55 |
| Nifedipine Er | Nifedipine | 79 | 21 |
| Topiramate | Topiramate | 71 | 18 |
| Losartan Potassium | Losartan Potassium | 70 | 22 |
| Clonidine Hcl | Clonidine Hcl | 69 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | suppressed |
| Baclofen | Baclofen | 60 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 25 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 55 | 18 |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 14 |
| Eliquis | Apixaban | 52 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 51 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 21 |
| Bumetanide | Bumetanide | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 11 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 14 |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | 11 |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Brilinta | Ticagrelor | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 15 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.97 · 6 records | Novo Nordisk Inc | MAVYRET, Ozempic, Rybelsus, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error